I am excited to be participating today as an invited speaker to the 1st Cambridge Stem Cell Institute Postdoc Symposium, where I will talk about the Gene Editing debate and the role of the bioethicist.
You can access the agenda of the symposium here
Many thanks to Dr Thomas Burgold for inviting me.
What follows is an excerpt of an op-ed I have recently published on the Huffington Post Blog with some reflections on the profession of the bioethicist:
“With my students in the MA in Bioethics & Society at King’s College London we spend one lecture at the beginning of the year discussing who and what the bioethicist is.
As I wrote on this blog before, it is, to say the least, a bit disheartening that we seem not to have made any progress in 40 years when it comes to governing science, and that we still refer to Asilomar as the exemplar of best practice for governing science.
Take, for example, the recent news that “US science leaders [are] to tackle the ethics of gene-editing technology.” The National Academy of Science, in what has been explicitly called a “step reminiscent of one in 1975, when NAS convened the Asilomar Conference” is putting together an international summit on gene editing this fall. The intention is – or so it seems – to bring together scientists to set the ethical policies by which scientists work on and with gene editing technologies.
In another example, Francis Collins Director of the NIH has released a statement that NIH will not fund research using gene editing technologies in human embryos. This comes before any engagement with ethics, and as rightly pointed out by Pete Mills of the Nuffield Council on Bioethics, it is equivalent to “throwing out the bathwater, baby and all.”
You can read the rest of the blog post here: